Literature DB >> 16186537

Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis.

Finn E Somnier1.   

Abstract

The incidence of myasthenia gravis (MG) from 1970 through 1999 was studied in an area with 2.3 million inhabitants. The mean annual incidence rate of early-onset MG was constant at 3.5 x 10(-6). In late-onset MG, the rate increased from 4.7 to 20.8 x 10(-6). The two onset types of MG may thus be distinct disorders. The author hypothesized that late-onset nonthymoma anti-acetylcholine receptor antibody-seropositive MG may be provoked by environmental factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186537     DOI: 10.1212/01.wnl.0000176067.32186.a3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

2.  Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.

Authors:  Roberto Massa; Giulia Greco; Manuela Testi; Emanuele Rastelli; Chiara Terracciano; Erica Frezza; Matteo Garibaldi; Girolama A Marfia; Franco Locatelli; Nicola B Mercuri; Eugenio Pompeo; Giovanni Antonini; Marco Andreani
Journal:  J Neurol       Date:  2019-02-11       Impact factor: 4.849

3.  Myasthenia gravis: a changing pattern of incidence.

Authors:  I Casetta; E Groppo; R De Gennaro; E Cesnik; L Piccolo; S Volpato; E Granieri
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

4.  Characteristics of late-onset myasthenia gravis.

Authors:  Saša A Zivković; Paula R Clemens; David Lacomis
Journal:  J Neurol       Date:  2012-04-05       Impact factor: 4.849

5.  [Myasthenia gravis should be considered in cases of Parkinson's disease and progressive dysphagia].

Authors:  P P Urban; O Stammel
Journal:  Nervenarzt       Date:  2018-04       Impact factor: 1.214

6.  Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?

Authors:  Gabriele Monte; Gregorio Spagni; Valentina Damato; Raffaele Iorio; Mariapaola Marino; Amelia Evoli
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

7.  The high frequency and clinical feature of seronegative myasthenia gravis in Southern China.

Authors:  Hui-Yu Feng; Hai-Yan Wang; Wei-Bin Liu; Xue-Tao He; Xin Huang; Chuan-Ming Luo; Yan Li
Journal:  Neurol Sci       Date:  2012-07-25       Impact factor: 3.307

8.  Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups.

Authors:  Liv Hapnes; Nick Willcox; Bergithe E V Oftedal; Jone F Owe; Nils Erik Gilhus; Anthony Meager; Eystein S Husebye; Anette S Bøe Wolff
Journal:  J Clin Immunol       Date:  2011-11-30       Impact factor: 8.317

Review 9.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

Review 10.  The emerging diversity of neuromuscular junction disorders.

Authors:  J Newsom-Davis
Journal:  Acta Myol       Date:  2007-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.